Does the pill version of Wegovy change the game for Novo Nordisk?
A new analysis report from investment bank Goldman Sachs raises its forecasts for Novo Nordisk, with a special emphasis on the oral version of the drug Wegovy.
According to analysts' estimates, revenue from this version alone is expected to reach $7 billion.
Geographically, the current forecast assumes that 90% of this revenue will come from the US market, which is currently considered the company's main focus for obesity treatment.
Meanwhile, here are some key points emerging from the field:
Analysts at Goldman Sachs, along with other sector experts, express deep impression with the actual sales volumes already achieved by oral Wegovy.
This success indicates rapid adoption of the product by patients.
Given the strong sales data, it is estimated that in the coming weeks and months, we will see additional financial institutions 'correcting' their forecasts upwards.
The transition from injection to pill is a real revolution for the average patient, which explains the high demand and impressive sales volumes.
Although the current forecast largely focuses on the US market, there is an interesting angle pointing to significant potential elsewhere in the world:
Some analysts believe that revenue from outside the United States will be significantly higher than the 10% threshold.
The main reason for this lies in the pricing strategy, as the price in the United States is set at a relatively low level, allowing for easier and faster penetration into international markets.
Novo Nordisk is trying to establish its position as a global leader, with the shift to more accessible and convenient solutions like pills, alongside competitive pricing, aiming to expand its target audience and provide a more effective solution for patients.
We are monitoring